20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Over £124k raised for Cure Parkinson’s at 2023 TCS London Marathon
On Sunday 23 April, 44 Cure Parkinson’s supporters laced up their trainers for the 2023 TCS London Marathon, raising an incredible amount for our research. Despite the rain #TeamCure hit the streets of London for the grueling 26.2 mile route, running past some of the…
A biomarker for Parkinson’s?
New research from an international consortium led by the Michael J Fox Foundation has highlighted a potential biological biomarker for Parkinson’s.
A new case for GCase
Low levels of a protein called GCase is associated with an increased risk of developing Parkinson’s. New understandings of the role of GCase could help to further explain other biological processes observed in the condition.
New clinical trials targeting the LRRK2 gene
LRRK2 is a protein that becomes hyperactive in some people with Parkinson’s, and this is believed to be involved in the progression of their Parkinson’s.
Just a lysosomal enzyme…
About 5% of individuals affected by Parkinson’s carry a genetic variation in a region of their DNA called the GBA1 gene. This area of DNA provides the instructions for making an enzyme called GCase, which is known to be involved in cellular waste disposal. Recently, however, researchers have discovered that GCase […]